NIKKEI 225
38,178.42 -95.63 (-0.25%) HANG SENG
17,763.03 0.00 (0.00%) CRUDE OIL
79.23 +0.23 (+0.29%) GOLD FUTURES
2,333.70 +22.70 (+0.98%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,951.68 -2,103.64 (-4.38%)
LadRx Corporation (0I5R.L)
- Business Wire
LadRx Issues 2024 Update to Shareholders
LOS ANGELES, January 09, 2024--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below letter to shareholders providing a corporate update and anticipated milestones for 2024 regarding arimoclomol and LADR-7.
- Business Wire
LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation
LOS ANGELES, June 22, 2023--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that it has transferred the royalty and milestone rights associated with arimoclomol and aldoxorubicin to XOMA Corporation (NASDAQ: XOMA) ("XOMA"). In exchange for the future rights to royalties and milestones on arimoclomol and aldoxorubicin, the agreement provides to LadRx $5 million in gros
- Business Wire
LadRx Announces Reverse Stock Split
LOS ANGELES, May 10, 2023--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 100 pre-split shares. The reverse stock split will become effective at 5:00 a.m. PDT on Wednesday, May 17, 2023. The Company’s common stock will continue to be traded on the OTC Capita
